Sugi Predict

Sugi Predict / Compounds / SCHEMBL162875

SCHEMBL162875

SCHEMBL162875

CCNc1ccccc1[N+](=O)[O-]

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KAT2B Q92831 2/20 0.60
▸ MAPT P10636 5/20 0.57
▸ L3MBTL1 Q9Y468 3/20 0.57
▸ MAPK1 P28482 2/20 0.57
▸ LMNA P02545 1/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ MEN1 O00255 1/20 0.56
▸ NPC1 O15118 1/20 0.55
▸ RAB9A P51151 1/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.55
▸ HCAR3 P49019 1/20 0.55
▸ ALDH1A1 P00352 3/20 0.55
▸ CASP7 P55210 1/20 0.55
▸ TDP1 Q9NUW8 1/20 0.55
▸ IDO1 P14902 1/20 0.53
▸ HTT P42858 1/20 0.52
▸ TP53 P04637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3652036 0.98 KAT2B (0.61) KAT2BMAPTL3MBTL1MAPK1LMNA
Bromide SCHEMBL28202540 0.98 KAT2B (0.58) KAT2BMAPTL3MBTL1MAPK1LMNA
Phosphoric Acid SCHEMBL637835 0.92 KMT2A (0.53) KAT2BMAPTL3MBTL1MAPK1LMNA
SCHEMBL4077151 0.85 KAT2B (0.66) KAT2BMAPTL3MBTL1MAPK1LMNA
SCHEMBL29516821 0.84 KAT2B (0.64) KAT2BMAPTL3MBTL1MAPK1LMNA
SCHEMBL9781715 0.84 KAT2B (0.64) KAT2BMAPTL3MBTL1MAPK1LMNA
SCHEMBL6198859 0.84 KAT2B (0.80) KAT2BMAPTL3MBTL1MAPK1LMNA
SCHEMBL981345 0.82 KAT2B (0.71) KAT2BMAPTL3MBTL1MAPK1LMNA
SCHEMBL16655113 0.81 KAT2B (0.57) KAT2BMAPTL3MBTL1MAPK1LMNA
SCHEMBL11122816 0.81 KAT2B (0.57) KAT2BMAPTL3MBTL1MAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240350609-A1 METHODS FOR IMPROVING THE ADSORPTION OF POLYSACCHARIDE-PROTEIN CONJUGATES AND MULTIVALENT VACCINE FORMULATION OBTAINED THEREOF SERUM INSTITUTE OF INDIA PRIVATE LIMITED (IN) 2024-10-24 — — US claimed
EP-4450082-A1 METHODS FOR IMPROVING THE ADSORPTION OF POLYSACCHARIDE-PROTEIN CONJUGATES AND MULTIVALENT VACCINE FORMULATION OBTAINED THEREOF Serum Institute Of India Private Limited (IN) 2024-10-23 — — EP claimed
US-20240293524-A1 MULTIPLE FUNCTIONALIZED noMV CONJUGATES GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2024-09-05 — — US claimed
US-20230137914-A1 nOMV-ANTIGEN CONJUGATED COMPOUNDS AND USE THEREOF GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) 2023-05-04 — — US claimed
EP-4025246-A2 IMMUNOGENIC COMPOSITIONS AGAINST ENTERIC DISEASES AND METHODS FOR ITS PREPARATION THEREOF Serum Institute Of India Private Limited (IN) 2022-07-13 — — EP claimed
CN-114728053-A Immunogenic compositions against intestinal disease and process for preparing same 印度血清研究所私人有限公司 2022-07-08 — — CN claimed
US-20220008529-A1 MULTI-FUNCTIONALIZED noMV CONJUGATES GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2022-01-13 — — US claimed
EP-3799883-A1 NOMV-ANTIGEN CONJUGATED COMPOUNDS AND USE THEREOF GlaxoSmithKline Biologicals S.A. (BE) 2021-04-07 — — EP claimed
WO-2021044436-A2 IMMUNOGENIC COMPOSITIONS AGAINST ENTERIC DISEASES AND METHODS FOR ITS PREPARATION THEREOF SERUM INSTITUTE OF INDIA PRIVATE LIMITED (IN) 2021-03-11 — — WO claimed
CN-111646911-A Method for synthesizing o-aminoacetophenone 广东莱佛士制药技术有限公司 2020-09-11 — — CN claimed
EP-3544637-A1 nOMV-ANTIGEN CONJUGATES AND USE THEREOF GlaxoSmithKline Biologicals S.A. (BE) 2019-10-02 — — EP claimed
WO-2019030271-A1 MULTI-FUNCTIONALIZED nOMV CONJUGATES GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2019-02-14 — — WO claimed
CN-108778322-A Pseudomonas aeruginosa PCRV linked antigen vaccine 葛兰素史密丝克莱恩生物有限公司 2018-11-09 — — CN claimed
EP-3365004-A1 P. AERUGINOSA PCRV-LINKED ANTIGEN VACCINES GlaxoSmithKline Biologicals S.A. (BE) 2018-08-29 — — EP claimed
WO-2018096013-A1 nOMV-ANTIGEN CONJUGATES AND USE THEREOF GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) 2018-05-31 — — WO claimed
CN-104519910-B Adjuvanted formulations of streptococcus pneumoniae antigens 诺华股份有限公司 2017-05-03 — — CN claimed
WO-2017067964-A1 P. AERUGINOSA PCRV-LINKED ANTIGEN VACCINES GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) 2017-04-27 — — WO claimed
CN-104519910-A Adjuvanted formulations of streptococcus pneumoniae antigens NOVARTIS AG 2015-04-15 — — CN claimed
EP-2822586-A1 ADJUVANTED FORMULATIONS OF STREPTOCOCCUS PNEUMONIAE ANTIGENS Novartis AG (CH) 2015-01-14 — — EP claimed
WO-2013131983-A1 ADJUVANTED FORMULATIONS OF STREPTOCOCCUS PNEUMONIAE ANTIGENS NOVARTIS AG (CH) 2013-09-12 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230137914-A1 nOMV-ANTIGEN CONJUGATED COMPOUNDS AND USE THEREOF VAPB, CD14, CHMP4B KAT2B 2800/4885MAPT 481/4885L3MBTL1 3779/4885
US-20240350609-A1 METHODS FOR IMPROVING THE ADSORPTION OF POLYSACCHARIDE-PROTEIN CONJUGATES AND MULTIVALENT VACCINE FORMULATION OBTAINED THEREOF DDOST, CD14, STT3B KAT2B 3891/4885MAPT 1888/4885L3MBTL1 3463/4885
US-20240293524-A1 MULTIPLE FUNCTIONALIZED noMV CONJUGATES CD14, VAPB, CHMP4B KAT2B 3267/4885MAPT 1013/4885L3MBTL1 3615/4885
US-20220008529-A1 MULTI-FUNCTIONALIZED noMV CONJUGATES CD14, CHMP4B, VAPB KAT2B 3052/4885MAPT 1199/4885L3MBTL1 3590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.